0001104659-17-072537.txt : 20171208
0001104659-17-072537.hdr.sgml : 20171208
20171208162911
ACCESSION NUMBER: 0001104659-17-072537
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171206
FILED AS OF DATE: 20171208
DATE AS OF CHANGE: 20171208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chan Barbara Y
CENTRAL INDEX KEY: 0001676343
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17082
FILM NUMBER: 171247426
MAIL ADDRESS:
STREET 1: C/O AEGERION PHARMACEUTICALS INC.
STREET 2: ONE MAIN ST., SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NOVELION THERAPEUTICS INC.
CENTRAL INDEX KEY: 0000827809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O NORTON ROSE FULBRIGHT
STREET 2: 1800 - 510 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6B 0M3
BUSINESS PHONE: (877) 764-3131
MAIL ADDRESS:
STREET 1: C/O NORTON ROSE FULBRIGHT
STREET 2: 1800 - 510 WEST GEORGIA STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6B 0M3
FORMER COMPANY:
FORMER CONFORMED NAME: QLT INC/BC
DATE OF NAME CHANGE: 20000608
FORMER COMPANY:
FORMER CONFORMED NAME: QLT PHOTO THERAPEUTICS INC
DATE OF NAME CHANGE: 19960618
FORMER COMPANY:
FORMER CONFORMED NAME: QUADRA LOGIC TECHNOLOGIES INC
DATE OF NAME CHANGE: 19941201
4
1
a4.xml
4
X0306
4
2017-12-06
0
0000827809
NOVELION THERAPEUTICS INC.
NVLN
0001676343
Chan Barbara Y
C/O NOVELION THERAPEUTICS INC.
1800-510 WEST GEORGIA STREET
VANCOUVER, BRITISH COLUMBIA
A1
V6B OM3
BRITISH COLUMBIA, CANADA
0
1
0
0
See Remarks
Common Shares
2017-12-06
4
F
0
1216
3.33
D
13784
D
Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.
The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of 3,750 restricted stock units on December 6, 2017.
This total includes 11,250 unvested restricted stock units which were granted on December 6, 2016 and were reported in Table II, as well as the shares settled after the tax withholding and vesting event described in footnote number 2. Each restricted stock unit represents a contingent right to receive one common share of the Issuer.
President and Chief Accounting Officer of Aegerion Pharmaceuticals, Inc.
/s/ Jennifer Fitzpatrick, attorney-in-fact
2017-12-08